Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Karyopharm Therapeutics

Thumbnail
July 24, 2019

Biogen leads the way in renewed amyotrophic lateral sclerosis push

The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.

Thumbnail
July 19, 2019

Novel drug approvals head for a down year

With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.

Article image
Vantage logo
July 04, 2019

Karyopharm rollercoaster ends in selinexor approval

Positive data, toxicity, a US FDA delay and the early leaking of information culminate in a green light for the multiple myeloma drug.

Article image
Vantage logo
June 28, 2019

Go or no go? Karyopharm awaits a verdict on selinexor

A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.

Article image
Vantage logo
February 27, 2019

Adcom gives Karyopharm a second chance with selinexor

Incredibly, a US FDA panel has left the door open for approval of Karyopharm’s selinexor in multiple myeloma, despite concerns about safety.

Article image
Vantage logo
January 17, 2019

As the US shutdown rolls on, blockbuster launches line up for 2019

A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?

Article image
Vantage logo
August 14, 2018

Most valuable unpartnered assets reveal a changing of the guard

Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.

Vantage logo
May 17, 2018

Asco preview – Loxo shines amid small-molecule effort

Vantage logo
May 01, 2018

Karyopharm hopes to Storm the multiple myeloma market

Vantage logo
March 23, 2018

Upcoming events – Karyopharm and Aveo hope data can satisfy US regulators

Article image
Vantage logo
January 30, 2018

Biogen burned as Forward goes backwards

Biogen might be wondering what else it could have spent $1.2bn on as Forward Pharma's patent challenge against Tecfidera falters.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.